BioCentury
ARTICLE | Clinical News

Stealth begins Phase II/III of elamipretide in Barth syndrome

August 10, 2017 5:01 PM UTC

Stealth BioTherapeutics Inc. (Newton, Mass.) began the double-blind, crossover, U.S. Phase II/III TAZPOWER trial to evaluate subcutaneous elamipretide (MTP-131) in ≥12 patients ages ≥12 with genetically confirmed Barth syndrome.

Patients will receive 40 mg elamipretide or placebo once daily for 12 weeks. After a 4-week washout period, patients will then cross over to the other treatment for 12 weeks...

BCIQ Company Profiles

Stealth BioTherapeutics Corp.

BCIQ Target Profiles

Cardiolipin